Most cases of primary hyperparathyroidism result from a single adenoma. Surgical treatment with minimally invasive parathyroidectomy (MIP), therefore, demands accurate preoperative localization of the ...

November 5, 2007 (San Francisco) — A number of assays that test for intact parathyroid hormone levels (iPTH) are not appropriate for use with the National Kidney Foundation's Kidney Disease Outcomes ...

Since the original report, in 1963, 1 of the development of a radioimmunoassay for parathyroid hormone based on the bovine hormone, assays have been independently developed in several centers in this ...

A slow decrease in PTH may also be caused by a prolonged half-life and not necessarily by additional hyperfunctioning glands. [7] We performed PTH measurement after 10 minutes and if a sufficient ...

Current methods for the noninvasive assessment of bone turnover are not useful for the diagnosis of renal osteodystrophy in patients with chronic kidney disease (CKD), reports a new study. The study ...

Parathyroid hormone (PTH) is an 84 amino acid that plays a key role in phosphocalcic metabolism. Its measurement is essential to diagnose and treat primary hyperparathyroidism and to evaluate chronic ...

Hyperparathyroidism is a condition wherein the parathyroid glands create too much parathyroid hormone. This can cause the levels of calcium in the blood to rise, which, without treatment, can lead to ...

Parathyroid cancer is very rare. Most cases of parathyroid disease, including almost all cases of overactive parathyroid, are not cancer. At Fred Hutchinson Cancer Center, our endocrine tumor ...

A RARE syndrome consisting of basal-cell nevi § and bone defects — namely, mandibular cysts and rib abnormalities 1–4 — has been described. Hypertelorism, mental changes, agenesis of the corpus ...

Patient-derived parathyroid organoids (PTOs) could pave the way for future physiology studies and drug-screening applications, as shown in a new study. Patient-derived parathyroid organoids (PTOs) ...